نظرة عامة

Mylorge is a dasatinib (monohydrate) film-coated tablet, a BCR-ABL tyrosine kinase inhibitor used in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

Tyrosine kinase inhibitor
Oncology

تواصل مع المُصنّع عرض الكتالوج

أبرز ميزات المنتج

Contains dasatinib monohydrate, a BCR-ABL tyrosine kinase inhibitor
Available in 20 mg, 50 mg, 70 mg and 100 mg film-coated tablets
Supplied in 30- or 60-tablet packs depending on strength

تفاصيل المنتج

الاستخدام	Prescription medicine
Active ingredient	Dasatinib monohydrate
Dosage form	Film-coated tablet
Available strengths	20, 50, 70, 100 mg

التصنيف

التخصصات
طريقة الإعطاء
التركيز
تصنيف ATC
الشكل الصيدلاني
المادة الفعالة
حالة الوصفة الطبية

المزايا التنافسية

Regulatory Certification

Licensed by the Turkish Medicines and Medical Devices Agency (TİTCK)

Clinical Indication

Treatment of chronic myeloid leukemia (CML)
Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)

Packaging Logistics

30 or 60 tablets per pack depending on strength

1 من 3

الإصدار	Strength	Pack size	Dosage form	Catalogue number
Mylorge 20 mg Film-Coated TabletDasatinib monohydrate 20 mg film-coated tablet, 60-tablet pack.	20 mg	60 tablets	Film-coated tablet	60 Tablet
Mylorge 50 mg Film-Coated TabletDasatinib monohydrate 50 mg film-coated tablet, 60-tablet pack.	50 mg	60 tablets	Film-coated tablet	60 Tablet
Mylorge 70 mg Film-Coated TabletDasatinib monohydrate 70 mg film-coated tablet, 60-tablet pack.	70 mg	60 tablets	Film-coated tablet	60 Tablet
Mylorge 100 mg Film-Coated TabletDasatinib monohydrate 100 mg film-coated tablet, 30-tablet pack.	100 mg	30 tablets	Film-coated tablet	30 Tablets

Mylorge

الإصدارات